Wellnex Life (ASX:WNX): Wellnex Publishes Admission Document to LSE AIM

• Wellnex Life has published an Admission Document for its dual listing on the AIM market of the London Stock Exchange, with admission expected on Friday 21 March 2025.
• The dual listing on the AIM market is a pivotal moment for Wellnex Life that will assist in continuing the Company’s growth in the consumer healthcare market.
• Concurrent with admission to the AIM market, Wellnex Life will extinguish the material deferred consideration for the Pain Away acquisition and the outstanding Convertible Notes totaling, in aggregate, $11.9 million, saving the Company $1.4 million annually in interest costs and fees significantly improving the Company’s balance sheet.

Wellnex Life's Joint Managing Director Zack Bozinovski said:

“The publication of the Admission Document and the imminent admission to AIM, will not only save the company $1.4 million through the elimination of circa $11.9 million in debt, but it will also provide increased exposure and credibility to the Company as it launches its brands into the European market. This follows the UK launch, with Haleon, of our innovative liquid paracetamol soft gel. Wellnex Life has a Wellnex Life Limited Building 2, Level 3, Suite 69, 574 Plummer Street Port Melbourne VIC Australia info@wellnexlife.com.au Phone: +61 3 8399 9419 strong brand and product portfolio, and with a strengthened balance sheet, I am confident that it will have the necessary platform from which to grow revenues and margins.”